Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 799Uterine Cervical Neoplasms 537Endometrial Neoplasms 459Breast Neoplasms 221Fallopian Tube Neoplasms 198Colorectal Neoplasms 179Carcinoma, Non-Small-Cell Lung 163Neoplasms 137Stomach Neoplasms 127Pancreatic Neoplasms 118Prostatic Neoplasms 107Neoplasm Metastasis 107Melanoma 107Lung Neoplasms 103Carcinoma, Ovarian Epithelial 92Triple Negative Breast Neoplasms 91Squamous Cell Carcinoma of Head and Neck 82Esophageal Neoplasms 77Head and Neck Neoplasms 75Carcinoma, Renal Cell 75Urinary Bladder Neoplasms 74Uterine Neoplasms 66Vulvar Neoplasms 64Colonic Neoplasms 59Peritoneal Neoplasms 58Carcinoma, Hepatocellular 58Uterine Cervical Dysplasia 57Sarcoma 52Carcinoma, Transitional Cell 48Papillomavirus Infections 47

Interventions

Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Cancer Recurrent × Gynecologic × 1 year × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡